Sign In
Buy ACXP
$1.44
+0.0200 (+1.41%)
At Close: Jul 31, 2026
Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?
10:55am, Thursday, 19'th Mar 2026
The mean of analysts' price targets for Acurx Pharmaceuticals (ACXP) points to a 226.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Is Acurx Pharmaceuticals (ACXP) Outperforming Other Medical Stocks This Year?
10:41am, Tuesday, 17'th Mar 2026
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Apyx Medical (APYX) have performed compared to their sector so far this year.
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Sees Large Drop in Short Interest
01:40am, Sunday, 15'th Mar 2026
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP - Get Free Report) saw a significant decline in short interest in the month of February. As of February 27th, there was short interest totaling 57,707 shares,
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
01:02pm, Friday, 13'th Mar 2026
Acurx Pharmaceuticals, Inc. (ACXP) Q4 2025 Earnings Call Transcript
Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update
07:01am, Friday, 13'th Mar 2026
STATEN ISLAND, N.Y., March 13, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
Why Is Acurx Pharmaceuticals Stock Up Over 105% Today?
02:45pm, Wednesday, 11'th Mar 2026
Acurx Pharmaceuticals Inc (NASDAQ: ACXP) shares are trading sharply higher Wednesday afternoon despite a lack of company-specific news during the session. The move may reflect continued investor react
Acurx's Program in the Broader CDI Patient Population is Ready to Advance to Phase 3 International Clinical Trials Acurx is launching a ground-breaking clinical trial with ibezapolstat in patients wit
STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors
08:00am, Monday, 02'nd Feb 2026
STATEN ISLAND, N.Y., Feb. 2, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule
Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year?
10:40am, Tuesday, 06'th Jan 2026
Here is how Acurx Pharmaceuticals, Inc. (ACXP) and Adial Pharmaceuticals, Inc. (ADIL) have performed compared to their sector so far this year.
The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the mo
Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript
10:11am, Wednesday, 12'th Nov 2025
Acurx Pharmaceuticals, Inc. ( ACXP ) Q3 2025 Earnings Call November 12, 2025 8:00 AM EST Company Participants Robert Shawah - Co-Founder & CFO David Luci - Co-Founder, President, CEO, Corporate Secret
Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update
07:01am, Wednesday, 12'th Nov 2025
STATEN ISLAND, N.Y. , Nov. 12, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics
DNA polymerase (pol) IIIC inhibitors are an innovative new class of antibiotics, the first in more than 30 years, that target a critical enzyme of Gram-positive bacteria including C. difficile, MRSA,
Pioneering data demonstrate that Acurx's U.S. and EU Phase 3-ready DNA pol IIIC inhibitor, ibezapolstat (IBZ), has unique selective antibacterial activity in the gut which spares beneficial bile acid
